Trexquant Investment LP Cullinan Oncology, Inc. Transaction History
Trexquant Investment LP
- $8.35 Billion
- Q2 2025
A detailed history of Trexquant Investment LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 119,342 shares of CGEM stock, worth $1.02 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
119,342
Previous 68,467
74.31%
Holding current value
$1.02 Million
Previous $518,000
73.36%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
66.6MCall Options Held
10.6KPut Options Held
917K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$65.5 Million11.28% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$49.2 Million1.7% of portfolio
-
Lynx1 Capital Management LP San Juan, PR4.4MShares$37.7 Million9.81% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$33 Million0.67% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$30.4 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $390M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...